viDA has raised $6.0 million to date, with the last round led by BDC Venture Capital.  We have also secured non-dilutive,


peer reviewed grant funding of over $1.75 million. We are seeking additional funding to move our lead candidate through


IND enabling toxicology and safety pharmacology studies to file an Investigational New Drug application by Q4-2016


and position viDA for a Phase Ib clinical trial in Discoid Lupus Erythematosus patients. For more information about


investment opportunities with viDA, please


contact us.